Nanoviricides, Inc. · AMEX:NNVC
Nanoviricides — NIBA's 153rd Investment Conference 2026
23 slides from Nanoviricides's conference presentation, Oct 7, 2026
Slide 1: NV-387, A Broad-Spectrum Antiviral Presenting Revolutionary Strategies for Viral Infections
“Bind-Engulf-Destroy” Stock Symbol: NNVC (NYSE American) NV-387, A Broad-Spectrum Antiviral Presenting Revolutionary Strategies for Viral Infections Presented by: Presented at: Anil R. Diwan, PhD, The NIBA’s 153nd Investment Conference President & Exec. Chairman on: October 7, 2026, 12:10am adiwan@n
Slide 2: Disclosure Statement
Disclosure Statement NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only. NanoViricides, Inc.(www.nanoviricide
Slide 3: NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections
“Bind-Engulf-Destroy” Stock Symbol: NNVC NYSE American NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections NV-387 is Revolutionizing How to Fight DEADLY NOVEL VIRAL Outbreaks Phase II - NV-387 ORAL Treatment for Ebola Bundibugyo > Started Phase II - NV-387 ORA
Slide 4: NV-387 is Revolutionizing How to Fight Deadly Novel Viral Outbreaks
NV-387 is Revolutionizing How to Fight Deadly NOVEL VIRAL Outbreaks Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); … NOVEL VIRUS OUTBREAKS TODAY - NO TREATMENT IS AVAILABLE; - VACCINES, ANTIBODIES NOT MATCHED TO STRAIN IF AVAILABLE When New or Modified Virus Enters Localized Individuals But
Slide 5: NV-387 is Revolutionizing How to Fight Deadly Viral Outbreaks
NV-387 is Revolutionizing How to Fight Deadly VIRAL Outbreaks Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); … NV-387 is Broad-Spectrum and Could be Deployed Empirically for Early Response to Novel Viral Outbreaks (upon First approval) NV-387 is the ONLY ORAL TREATMENT in Phase II Clinical
Slide 6: Virus Situation: Novel Virus; No Current Treatment or Vaccine
NV-387 is Revolutionizing How to Fight Deadly VIRAL Outbreaks Ebola/Marburg; Mpox Clade I, II; Measles; (SARS-CoV-2); … Virus Situation Novel Virus; No Current Treatment or Vaccine Ebola Declared PHEIC by WHO May 17, 2026. Currently Limited to DRC. Now Kenya? Bundibugyo Over 8,400 Confirmed Cases; O
Slide 7: Imagine… NV-387 Revolutionizing Antiviral Therapy Like Penicillin
Moreover, Imagine… NV-387 is Revolutionizing Antiviral Therapy Like Penicillin Did for Bacterial Infections VIRUS INFECTION TREATMENT TODAY BACTERIAL INFECTIONS TREATMENT REVOLUTIONIZED BY ANTIBIOTICS THERAPY! 1. Patient Stays Home 2-3 days. 2. If Serious, Patient Goes to Doctor 1. Patient Stays Hom
Slide 8: NanoViricides Drugs Pipeline: Cure Most Viruses!
NanoViricides Drugs Pipeline: Cure Most Viruses! Animal Efficacy IND-Enabling Drug Substance Indication Lead Id. Eficacy Studies Phase I Phase II Phase III 1 MPox / Smallpox Ebola (BDBV) Attack Re-Infection Cycle RSV NV-387 is a Revolutionary Broad-Spectrum Antiviral that NV-387 Mimics the Host Cell
Slide 9: NanoViricides Has Drug Candidates For Large Markets
… NanoViricides Has Drug Candidates For Large Markets: WIN-WIN For Investor and Inventor Nanoviricide Drug Virus Family Market Size, Global Estimated PRV Eligible? Candidate 2025 2030 CAGR $ Billions $ Billions RSV NV-387 3.1 18% 7.0 - Influenza; H5N1 Bird Flu NV-387 5.0 8.35% 7.5 - Coronaviruses NV
Slide 10: POC In Vivo Broad-Spectrum Activity: NV-387 Effective in Lethal Animal Models
POC In Vivo Broad-Spectrum Activity: NV-387 Is Effective in Lethal Animal Models and is Superior/Equivalent to Existing Drugs & No Toxicity Against a Diverse Family of Viruses Target Indication Virus Family Animal Model % Survival Improvement Pediatric RSV RSV Balb-c Mice NV-387, PO Led to Full Surv
Slide 11: NanoViricides Superior to All Other Current Antiviral Technologies
NanoViricides Superior to All Other Current Antiviral Technologies MCM Technology Nanoviricides Small Chemicals Antibodies Vaccines Attribute NO. YES. NO. NO. Changing Virus Resistance to Viral Escape? Drug Remains Active in Not Amenable to Rapid Necessitates New Changing Virus Face of Changing Viru
Slide 12: Unique Drug Developer with Own cGMP-Capable Manufacturing Capability
NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability Discovery to Drug Product Capabilities In-House Nanomedicines Characterization Facility Virology BSL-2 Certified Lab Protect Proprietary Technology & Intellectual Property Highly Customizable and Flex
Slide 13: Strong Executive Team; Independent Board of Directors
Strong Executive Team Anil R. Diwan, PhD Krishna Menon, Meeta R. Vyas, MBA Jayant Tatake, PhD President & Exec. Chairman VMD,MRCS,PhD CFO VP, R&D Co-Founder Consulting Medical Officer 30+ years Experience in Corporate 30+ Years of Pharmaceutical Industry Led Uplisting to NYSE-Amer. in 2013 30+ Years
Slide 14: Thank you for your attention and guidance
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Company, “NNVC” www.nanoviricides.com Thank you for your attention and guidance. Please address additional inquiries/correspondence to: Scientific and Technical: Business, Finance & Contracts: Together We Can Destroy Viruses Anil R. Diwan
Slide 15: NanoViricides Technology Salient Features
NanoViricides Technology Salient Features Viruses Cannot Escape Nanoviricides Technology Drugs Because any changed variant still uses the same virus-binding features on human cells that are copied by our drug Nanoviricides Technology Drugs work Independent of Patient Immune Status Virus itself compr
Slide 16: Value Proposition of NV-387 Broad-Spectrum Antiviral
Introducing Value Proposition of NV-387-Broad-Spectrum Antiviral NV-387 Emperic Therapy of Viral Infections Made Feasible Some NV-387 Target Product Characteristics TRL 5+ : Phase I Healthy Subjects Completed Successfully NV-387, An SPG-Mimetic Nanoviricide is Designed to Work Against - Oral: NV-387
Slide 17: How Does NanoViricides Technology Achieve All This Magic? Later!
How Does NanoViricides Technology Achieve All This Magic? Later! © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 17
Slide 18: NanoViricides Regulatory Developments
NanoViricides Regulatory Developments NV-387 Clinical: Successful Phase I Completed NV-387 Phase II in MPox Patients in DRC Non-Clinical Studies Completed Rolling CTA Filing Completed GMP Manufacture of Drug Substance Implemented Initial Approval pre-Submission Received, May 2025 GMP Manufacture of
Slide 19: About NanoViricides, Inc.
About NanoViricides, Inc. Founded in USA with Inventors and Inventions in USA Clinical Stage Pharma Company with Unique Nanomedicines Technology NV-387 Successfully Completed Phase I in Healthy Subjects in India Phase II in DRC to Treat MPox Soon Fully USA-Based On-Shore cGMP Manufacturing of Drug S
Slide 20: Intellectual Property - Complete Freedom to Operate
Intellectual Property - NanoViricides Has Complete Freedom to Operate International Patents (PCT) have been filed and issued since 2006 and 2007 on the basic compositions of matter and use for encapsulation, anticancer, antiviral, and All of the intellectual property has been other applications. dev
Slide 21: Here Is How NanoViricides Technology Achieves All This Magic
Here Is How NanoViricides Technology Achieves All This Magic © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 21
Slide 22: Platform Technology: Novel Antiviral Mechanism of Action
NanoViricides Platform Technology => Novel Antiviral Mechanism of Action Schematic Structure Cell-Mimicking Nanomachines that Seek to Bind, Engulf and Destroy a Virus Particle Without Nanoviricide Homopolymer Immune System Assistance Specific Receptor PEG based- RES protection Aqueous Exterior Ligan
Slide 23: Again, Thank you for your attention and guidance
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Company, “NNVC” www.nanoviricides.com Again, Thank you for your attention and guidance. Please address additional inquiries/correspondence to: Scientific and Technical: Business, Finance & Contracts: Together We Can Destroy Viruses Anil R
NanoViricides — NIBA's 153rd Investment Conference 2026 on 6ix